DAWN - Day One Biopharmaceuticals, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$21.50
DETAILS
HIGH:
$21.50
LOW:
$21.50
MEDIAN:
$21.50
CONSENSUS:
$21.50
DOWNSIDE:
0.14%
About Day One Biopharmaceuticals, Inc. (https://dayonebio.com)
Operating as a clinical-stage biopharmaceutical entity, Day One Biopharmaceuticals, Inc. is dedicated to discovering and commercializing precise therapeutic options for individuals battling genetically defined cancers. A key asset is DAY101, an orally administered, brain-permeable type II pan-rapidly accelerated fibrosarcoma kinase inhibitor, currently undergoing Phase II clinical trials for young patients experiencing recurrent or worsening low-grade glioma. Additionally, the company is advancing Pimasertib, an oral small molecule designed to inhibit mitogen-activated protein kinase kinases 1 and 2. Established in 2018, Day One Biopharmaceuticals, Inc. maintains its primary operations in South San Francisco, California.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Jeremy Bender | Chief Executive Officer, President & Director | 1971 | $1,195,600 USD |
| Charles N. York | Chief Operating Officer & Chief Financial Officer | 1977 | $873,625 USD |
| Adam Dubow | General Counsel | 1967 | $762,995 USD |
| Davy Chiodin | Chief Development Officer | – | – |
| Elly Barry | Chief Medical Officer | – | – |
| Heather Adkins Huet | Chief Scientific Officer | – | – |
| Jaa Roberson | Chief People Officer | – | – |
| Joey Perrone | Senior Vice President of Finance & Investor Relations | – | – |
| John Stubenrauch | Chief Technology Officer | – | – |
| Lauren Merendino | Chief Commercial Officer | 1976 | – |
| Michael J. Vasconcelles | Head of Research & Development | 1963 | – |